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Background: Given that the assessment of health-related quality of life (HRQoL) is an essential outcome measure
to optimize chronic obstructive pulmonary disease (COPD) patient management, there is a need for a short and
fast, reliable and valid instrument for routine use in clinical practice. The objective of this study was to analyse the
relationship between the disease-specific Airways questionnaire (AQ20) and the generic 15D health-related quality
of life (HRQoL) instrument simultaneously in a large cohort of patients with COPD. We also compare the HRQoL of
COPD patients with that of the general population.
Methods: The AQ20 and 15D were administered to 739 COPD patients representing an unselected hospital-based
COPD population. The completion rates and validity of, and correlations among the questions and dimension
scores were examined. A factor analysis with varimax rotation was performed in order to find subsets of highly
correlating items of the questionnaires.
Results: The summary scores of AQ20 and 15D were highly correlated (r = - 0.71, p < 0.01). In AQ20 over 50% of
patients reported frequent cough, breathlessness during domestic work, and chest problem limiting their full
enjoyment of life. 15D results showed a noteworthy decrease of HRQoL in breathing, mobility, sleeping, usual activities,
discomfort and symptoms, vitality, and sexual activity (scores ≤ 0.75). Compared to the age- and gender-standardized
Finnish general population, the COPD patients were statistically significantly worse off on 13 of 15 dimensions.
Conclusions: The AQ20 and 15D summary scores are comparable in terms of measuring HRQoL in COPD patients.
The data support the validity of 15D to measure the quality of life in COPD. COPD compromises the HRQoL
broadly, as reflected by the generic instrument. Both questionnaires are simple and short, and could easily be used
in clinical practice with high completion rates.
Introduction
Chronic obstructive pulmonary disease (COPD), a ser-
ious debilitating condition with worldwide prevalence of
8-20% today, is estimated to be the third leading cause
of death by year 2020 [1-3]. Respiratory conditions in
COPD such as emphysema or chronic bronchitis, or
both, are related to (nearly) irreversible airway obstruc-
tion causing chronic cough or phlegm and breathless-
ness (dyspnea) [4]. Persistent and progressive dyspnea
forces into lifestyle adjustments, impairs patients’
health-related quality of life (HRQoL), and leads to dis-
ability. Since there is no medical or surgical cure for
COPD with prognostic significance, one of the principal
goals of the management of COPD is to improve
patient’s HRQoL by relieving symptoms and maintaining
patient’s physical and emotional capabilities [5].
HRQoL has become an established outcome measure
that can be used to monitor and manage COPD.
HRQoL can be evaluated by means of disease-specific or
generic instruments. The disease-specific instruments
focus on a particular condition and its effect on a
patient’s health [6,7]. Generic instruments are broad in
* Correspondence: witold.mazur@helsinki.fi
1Department of Medicine, Pulmonary Division, Helsinki University Central
Hospital, Haartmaninkatu 4, 00029 Helsinki, P.O. Box 372, Finland
Full list of author information is available at the end of the article
Mazur et al. Health and Quality of Life Outcomes 2011, 9:4
http://www.hqlo.com/content/9/1/4
© 2011 Mazur et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.their scope and applicability enabling the comparisons
between different diseases and their treatments. Instead
of concentrating on a single condition these question-
naires are designed to capture also the impact of co-
morbidities and other quality of life impairing factors.
Multiple profile questionnaires such as Short Form
36-item Questionnaire (SF-36), Sickness Impact Profile
(SIP), Nottingham Health Profile (NHP), have been
tested in COPD [8-15]. Multi-dimensional preference-
based utility scales enable cost-utility analyses that are
currently the most useful method in economic evalua-
tion of health care interventions. The most commonly
used generic utility instruments in pulmonary diseases
are the EQ-5D, the Health Utility Index (HUI) and the
15D [16-19]. Given that the assessment of HRQoL is an
essential outcome measure to optimise COPD patient
management and to evaluate the effectiveness of thera-
peutic interventions, there is a need for a reliable and
valid instrument for routine use in clinical practice.
The AQ20 and the 15D are two well-validated question-
naires that have been applied in the clinical assessments of
HRQoL of patients suffering from obstructive pulmonary
disorders such as asthma and COPD [6,7,20-27]. However,
to our knowledge, there has been no comparative evalua-
tion of these two questionnaires in COPD patients. In this
study in a large cohort of patients with COPD we compare
both these instruments and examine their applicability.
We assess the convergent validity of the generic 15D using
disease-specific AQ20 and examining the correlations
among the items of both instruments. In addition we
explore how and to what extent the HRQoL in patients




This study belongs to a large clinical study of a cohort
of COPD patients in Finland [28]. Shortly, all patients
with COPD who had visited the Pulmonary Clinics of
the Helsinki and Turku University Hospitals during the
years 1995-2006 were identified from the Hospital Dis-
charge Registries. The databases were screened by
ICD10 code J44.8 and contained all patients between 18
to 75 years of age. The inclusion criterion was a diagno-
sis of COPD based on post-bronchodilatation spirome-
try according to GOLD criteria [29]. The research visits
occurred during the years 2005-2007. All participants
(N = 844) gave their informed consent to allow the
research consortium to collect, merge, and analyze their
comprehensive medical history from all healthcare pro-
viders who had treated them during the past 5-10 years
and agreed to continue their follow-up on an annual
basis for the next 10 years [28].
The HRQoL of patients was compared with that of a
sample of the general Finnish population. The 15D data
for the general population came from the National
Health 2000 Health Examination Survey representing
the Finnish population aged 30 years and older [30]. For
this analysis those individuals were selected, who were
in the age range of the patients (N = 5604). This sample
was weighted to reflect the age and gender distribution
of the patients.
Assessment of the HRQoL
The HRQoL was assessed using the self-completed air-
way-specific AQ20 [21] and the generic 15D [31] instru-
ment. All participants filled in both questionnaires at
the same time during the research visit. The 15D instru-
ment is a generic, multidimensional, standardized, self-
administered evaluative tool of HRQoL that can be used
both as a single index measure, and as a profile measure
[31] http://www.15d-instrument.net/15D. It describes
the health status with 15 dimensions, namely: mobility,
vision, hearing, breathing, sleeping, eating, speech, elimi-
nation, usual activities, mental function, discomfort and
symptoms, depression, distress, vitality, and sexual activ-
ity. Each dimension comprises five answer options.
A single index score (the 15D score, also referred to
here as 15D summary score) is obtained by incorporat-
ing population-based preference weights to the dimen-
sions [31]. The maximum score is 1 (no problems on
a n yd i m e n s i o n )a n dt h em i n i m u ms c o r ei s0( b e i n g
dead). More generally, in all important properties (relia-
bility, validity, discriminatory power and responsiveness)
the 15D compares at least equally with other prefer-
ence-based generic HRQoL instruments such as the
EQ-5D, SF-6D and HUI3 [10,31,32]. The reliability,
validity and responsiveness of 15D questionnaire has
been established in a group of 59 patients with moder-
ate COPD [27]. The summary score correlated well with
commonly used clinical measures of symptoms, lung
function, and exercise capacity.
As the disease-specific instrument of HRQoL we used
the AQ20 questionnaire. AQ20 was developed in 1998
for use in asthma [21,25] and COPD [9,20] and trans-
lated into Finnish [21,25]. The AQ20 is a uni-dimen-
sional measure containing 20 items with “yes” responses
scored as 1, and “no” and “not applicable” scored as 0.
The scores of 1 are summed up to obtain the AQ20
summary score, which ranges from 0 to 20. Score 0
indicates no impairment. [6,7]. In terms of discrimina-
tive properties and responsiveness, the AQ20 was found
comparable with more complex questionnaires such as
St. George’s Respiratory Questionnaire (SGRQ) [12] and
Chronic Respiratory Disease Questionnaire (CRQ)
[24,33]. In a recent COPD study, the reproducibility of
Mazur et al. Health and Quality of Life Outcomes 2011, 9:4
http://www.hqlo.com/content/9/1/4
Page 2 of 9AQ20 and its excellent correlation with SGRQ were
further corroborated [20].
The Coordinating Ethics Committee of the Helsinki
and Uusimaa Hospital District approved the study
approach, and the permission to conduct this research
was granted by the Helsinki and Turku University Hos-
pitals. All recruitment processes were well documented,
the study personnel trained, and monitored to meet the
standards of good clinical practice.
Statistical analysis
All analyses were performed by the statistical software
packages SPSS (version 16.0; Chicago, IL, USA). The dis-
tribution of responses across the two instruments, speci-
fically at the top and bottom of the scale, was examined
to identify possible ceiling or floor effects. Factor analysis
technique was used to reduce and rearrange the items of
the two instruments and thus identified the factors of
related variables e.g. the groups of questions that mea-
sured the related components of HRQL in each question-
naire separately. To compare the factors, the factor
analysis with orthogonal varimax rotation was performed,
and maximum likelihood was used as the extraction
method. Factors with eigenvalues 1 or greater were con-
sidered significant. Spearman’s correlation coefficient (R)
was used to estimate the correlation between the original
items and the factor scores of both instruments. A p <
0.05 was considered significant.
Results
Patient recruitment and selection
A total of 844 patients participated in the study.
A detailed description of thec o h o r ti n c l u d i n gac o m -
plete list of inclusion and exclusion criteria has been
published elsewhere [28]. Briefly, the previously given
COPD diagnosis was re-evaluated. This evaluation led to
the exclusion of 105 patients. Thus, a final cohort of 739
eligible patients (mean age ± SD; 64 ± 6.8 years, N =
473 men) with COPD and smoking-related symptomatic
chronic bronchitis was included in the analyses. Basic
clinical characteristics for the 739 participants of the
study are shown in the original publication [28].
Evaluation of the HRQoL
All the participants returned the HRQoL questionnaires.
The proportions of ambiguous and missing responses per
question in the HRQoL questionnaires were between
1-2%. Compared to the age- and gender-standardized
Finnish general population, the COPD patients were sta-
tistically significantly worse off on all 15D dimensions
except “mental function” and “discomfort and symptoms”
( F i g u r e1 ) .T h em e a n1 5 Ds c o r eo ft h eC O P Dp a t i e n t s
was 0.79 (± SD 0.11), which was significantly lower
than that of the age- and gender-standardized general
population (0.89 ± SD 0.09, p < 0.001). The 15D results
showed a substantial decrease of HRQoL on several
dimensions, especially in breathing, mobility, sleeping,
usual activities, discomfort and symptoms, vitality, and
sexual activity (scores ≤ 0.75) (Table 1). In the COPD
patients the mean AQ20 summary score was 8.25 (± SD
5.0). In AQ20 more than 50% of the patients reported
frequent cough, breathlessness during domestic work,
and chest problem limiting the patient fully enjoy their
life (Table 2). The AQ20 summary scores showed a small
“ceiling effect": 33 patients (4.5%) did not present any
respiratory symptoms and scored the best possible result
(score 0). For the 15D, the highest possible score (= 1)
was observed in 8 patients.
Correlations between the 15D with AQ20 questionnaires
in COPD patients
The 15D and AQ20 summary scores were highly corre-
lated (R = - 0.71, p < 0.01) (Figure 2). Due to the oppo-
site scales, all correlations were negative. The factor
analysis yielded 4 factors for both questionnaires
accounting for 42% of the total variance in 15D and
38% in AQ20 (Table 3). The identified factors were par-
tially similar. The most important factor in both ques-
tionnaires identified was ‘Limitations in physical activity’
(16% and 13% of variance, respectively). Both question-
naires also identified an emotional dimension among
the patients. ‘Psychic wellbeing’ explained 15% of var-
iance in 15D and ‘Emotional concern’ 9% in AQ20.
AQ20 found also factors for symptoms at rest and dur-
ing daily/social activities, factors that were missing from
15D. In order to estimate the degree to which the fac-
tors are inter-correlated, the resultant four factors were
compared in a simple correlation matrix. The factor
‘Limitations in physical activity’ in 15D correlated signif-
icantly with the factors ‘Limitations in physical activity’
(R = - 0.65, p < 0.0001), ‘Symptoms at rest’ (R = - 0.22,
p < 0.0001), and ‘Emotional concern’ (R = - 0.31, p <
0.0001), and ‘Limitations in daily activities’ (R = - 0.19,
p < 0.0001) in AQ20. ‘Psychic wellbeing’ in 15D corre-
lated significantly with ‘Symptoms at rest’ (R = - 0.30,
p < 0.0001) and ‘Emotional concern’ in AQ20 (R = - 0.34,
p < 0.0001). ‘Capability of thinking and speaking’ in 15D
correlated with ‘Symptoms at rest’ (R = - 0.22, p <
0.0001) and ‘Emotional concern’ of AQ20 (R = - 0.16, p <
0.0001), and ‘Limitations in daily activities’ (R = - 0.13,
p < 0.002). ‘Eating’ in 15D correlated with ‘Limitation in
physical activity’ (R = - 0.09, p < 0.02), and ‘Symptoms at
rest’ (R = - 0.15, p < 0.0001) in AQ20. The individual
questions of AQ20 correlated strongly (R from -0.40 to -
0.54) with the 15D dimensions of mobility (AQ20 items
3, 10, 12, 13), breathing (AQ20 items 3, 10, 11, 12, 13, 17,
20), usual activities (AQ20 items 3, 11, 13, 17, 20), and
vitality (AQ20 items 3, 11, 13, 17, 20). There existed a
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sexual functioning in the whole cohort (R = - 0.48, p =
0.01). The lowest or not significant correlations were
observed for vision, hearing, eating, elimination and
speech (data not shown).
Discussion
To our knowledge, the present report is the first study
to evaluate the HRQoL in a large unselected hospital-
based population of patients with stable COPD using
the 15D as a generic HRQoL measure and the AQ20 as
a disease-specific HRQoL measure at the same time.
COPD compromises the HRQoL widely, as reflected by
the generic instrument 15D, which demonstrated a
clearly poorer quality of life in the patients compared
with the general population sample in 13 of the 15
dimensions evaluated. Scores of the corresponding ques-
tions and dimensions of AQ20 and 15D, respectively,
and the summary scores of both instruments correlated
significantly, supporting the convergent validity of 15D
to evaluate quality of life in COPD. The study showed
that both the questionnaires comprise common ele-
ments, but also instrument-specific features. Further-
more, both questionnaires are simple and short, and
could easily be used in clinical practice with high
response and completion rates.
Contrary to conventional respiratory HRQoL measures
AQ20 is less comprehensive, although fully applicable to
COPD [22,24]. The great advantage of the questionnaire
is that it includes only 20 questions, which are easy and
quick for the patient to fill in (4 minutes) and for the
researcher to score (8 seconds). A small ‘ceiling effect’
was observed in the study population, most likely due to
the simple design of the 20 items with 0/1 responses
Figure 1 The mean (SEM) values of the 15D dimensions in the patients with COPD disease and the control subjects from the general
population. * p < 0.001.
Table 1 Summary of the participants’ responses to the
questions in the 15D questionnaire.
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avoidance of certain physical activities [24]. In order to
omit this potential limitation, Chen and colleagues
examined a modified version of AQ20, but did not
observe a significant impact in its performance [23]. In
this unselected hospital based COPD cohort, the mean
summary score of AQ20 is consistent with the scores
reported previously in COPD (8.33 vs. 5.9 - 9.9, respec-
tively) [20,23,24]. However, in previous studies the sam-
ple sizes have been small (less than 200 study subjects)
and gender distribution biased significantly towards
males. Since our study design was cross sectional we
were unfortunately not able to assess the evaluative
properties of the AQ20 such as responsiveness.
The most substantial advantage of the generic prefer-
ence-based utility HRQoL instruments is that they allow
comparisons across diseases and cost-utility or cost-
effectiveness analyses in health care. The main concern
is whether these instruments are explicit and sensitive
enough in specific diseases, especially at their mild and
moderate disease’s stages. In COPD few preference
instruments, such as the EQ-5D, the Quality of Well
Being Scale (QWB), or the HUI have been used
[13,14,17,19,34-37], some of them with ambiguous
results. A descriptive section of the EQ-5D has shown
substantial ceiling effect [19,38]. One reason for this
could be a three level classification of the health pro-
blem in comparison to 15D which allows the patient to
express the problem on five levels. The ceiling effect is
better avoided in the second part of the EQ-5D when
visual analog scale (VAS) is used as a “health thermo-
meter”. In VAS patients’ health status is evaluated on a
continuous scale between the worst and the best ima-
ginable health (scale 0-100). VAS has performed well in
COPD studies and provided reliable and valid scores
[19,39]. Direct comparisons of multiple health status
instruments suggest that QWB may be less responsive
in detecting health changes in patients who have under-
gone pulmonary rehabilitation than some of the disease-
specific measures [40,41]. The 15D instrument has been
previously used in COPD twice with different objectives.
Compared to EQ-5D 15D was found more attractive
due to better reliability and responsiveness in moderate
COPD when co-morbidities were excluded [27]. In a
large Finnish population survey (N = 6681), a total of 29
chronic conditions were studied using 15D and EQ-5D
simultaneously [26]. Although formal comparisons of
the two HRQoL measures were not performed, this
study found significant and systematic differences in the
rank order of disease severity between the two measures.
Table 2 Summary of the participants’ responses to the questions in the AQ20 questionnaire
Number Question Number of subjects answered
“Yes” (%)
AQ 1 Do you suffer from coughing attacks during the day? 403 (55)
AQ 2 Because of your chest trouble do you often feel restless? 311 (42)
AQ 3 Because of your chest trouble do you feel breathless maintaining the garden? 466 (64)
AQ 4 Do you worry when going to a friend’s house that there might be something there that will set off
an attack of chest trouble?
114 (15)
AQ 5 Do you suffer from chest symptoms as a result of exposure to strong smells, cigarette smoke or
perfume?
361 (49)
AQ 6 Is your partner bothered by your chest trouble? 228 (31)
AQ 7 Do you feel breathless while trying to sleep? 213 (29)
AQ 8 Do you worry about the long term effects on your health of the drugs that you have to take because
of your chest trouble?
232 (32)
AQ 9 Does getting emotionally upset make your chest trouble worse? 352 (48)
AQ 10 Because of your chest trouble are there times when you have difficulty getting around the house? 161 (22)
AQ 11 Because of your chest trouble do you suffer from breathlessness carrying out activities at work? 349 (48)
AQ 12 Do you feel breathless walking upstairs because of your chest trouble? 630 (85)
AQ 13 Because of your chest trouble do you suffer from breathlessness doing housework? 342 (46)
AQ 14 Because of your chest trouble do you go home sooner than others after a night out? 116 (16)
AQ 15 Because of your chest trouble do you suffer from breathlessness when you laugh? 97 (13)
AQ 16 Because of your chest trouble do you often feel impatient? 217 (30)
AQ 17 Because of your chest trouble do you feel that you cannot enjoy a full life? 443 (60)
AQ 18 Do you feel drained after a cold because of your chest trouble? 396 (54)
AQ 19 Do you have a feeling of chest heaviness? 351 (47)
AQ 20 Do you bother much about your chest trouble? 316 (43)
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Table 3 Rotated factor loadings of the factors of the original items of the 15D questionnaires and the AQ20
questionnaire
15D questionnaire AQ20 questionnaire
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All factors with eigenvalues more >1 and factor loading ≥0.4 were included, maximum likelihood was chosen as the extraction method. The rotational method
used was orthogonal, e.g. Varimax.
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diseases while EQ-5D ranked COPD as less severe.
Furthermore, like in most of the conditions studied, the
HRQoL loss (standardised for a number of variables)
was greater measured by the EQ-5D than by the 15D,
but the former presented a much higher ceiling effect
(25% vs. 5%, respectively). In the present study the
mean HRQoL was lower compared to that in the survey
(mean 15D score 0.79 vs. 0.84) most probably due older
mean age and hospital-based recruitment biasing the
cohort potentially towards more severe cases.
By definition the airway-specific and generic instru-
ments focus on a single or multiple conditions, respec-
tively, related to individual’sH R Q o L .I nt h i ss t u d yi n
the unselected population of COPD patients we found
that the two HRQoL scales are highly correlated
(assuming from the summary scores). These correlation
data lend support for the assertion that the two instru-
ments measure something similar. The factor analysis
suggests that the instruments measure different aspects
of the same concept, namely the overall effect of COPD
on an individual’s physical, psychical and emotional
health. The first factor, generated from the two instru-
ments, applies to the key problem caused by COPD, i.e.
the limitation in physical activity relating to varying
degrees in shortness of breath. Patients with COPD in
general have a higher prevalence of depression and anxi-
ety [42], and evidence suggests that these mental disor-
ders account for a significant amount of variance in
HRQoL, above and beyond the contributions of COPD
severity.
The limitation of physical activity due to COPD can
theoretically diminish a sexual function of patients.
S e x u a l i t yi sat o p i ct h a th a sr a r e l yb e e ns t u d i e di n
COPD patients and this item is evidently unrecognized
by airway disease-specific questionnaires. As a more
comprehensive instrument the 15D, contrary to other
generic, including preference-based instruments, covers
sexual functioning. Interestingly, in our study sexual
functioning correlated significantly to respiratory symp-
toms. The correlation was at the same level as with
mobility, breathing, usual activities, and vitality. The
sexual quality of life was negatively affected in both gen-
ders, but men reported significantly worse sexual func-
tion (data not shown). One reason for that could be an
erectile dysfunction reported in a study of outpatients
with COPD varying with the disease severity [43].
Insufficient data have been published on the use of
HRQoL instruments in clinical practice. The use of the
HRQoL instruments in everyday clinical settings is lim-
ited by several factors. One obvious limitation is time:
most questionnaires are time-consuming and therefore
incompatible with everyday clinical practice. Respecting
the clinician needs for short and fast, self-administered,
valid and relevant instruments to measure HRQoL in
COPD, the 15D tool could provide a means of eliciting
information on areas which are otherwise difficult to
identify and address during routine visits. Moreover,
recent studies show clearly that COPD can no longer be
regarded as a disease involving the lungs only. [37-39].
The 15D instrument captured the impact of both pul-
monary and extra-pulmonary manifestations of the
COPD patients and thus, offers an interesting and versa-
tile choice not only to monitor COPD, but also assist
clinician’s decisions.
Furthermore, compared to respiratory specific instru-
ments, a great advantage of this questionnaire is that,
alike other generic preference-based instruments, it
allows simultaneous cost-utility comparisons between
different treatment interventions in COPD and even
between other chronic conditions essential in public
health care with limited resources.
Conclusions
Scores of the corresponding questions and dimensions
of AQ20 and 15D, respectively, and the summary scores
of both instruments are comparable in terms of measur-
ing HRQoL in COPD patients. The results of this com-
parative analysis support the convergent validity of 15D
to measure the quality of life in COPD. COPD compro-
mises the HRQoL broadly, as reflected by the generic
instrument. Both questionnaires are simple and short,
and could easily be used in clinical practice with high
response and completion rates.
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